title: Treatment of fibroadenomatous hyperplasia in cats with aglépristone.
abstract: Fibroadenomatous hyperplasia (FAH) is characterized by a rapid proliferation of mammary stroma and duct epithelium of 1 or more glands and predominantly affects younger female cats. Endogenous progesterone and exogenous progestogens play an important role in the genesis of FAH. The presence of progesterone receptors in fibroadenomatous tissue allows for targeted endocrine therapy with progesterone receptor blockers. We report on 22 young cats with FAH, none of which had responded to the withdrawal of progestogens or ovariectomy. The common signs were tachycardia (11 cats); skin ulceration, painful mammary glands, or both (16 cats); lethargy (8 cats); and anorexia (4 cats). The cats were treated with subcutaneous injections of the progesterone receptor blocker aglépristone on 1 (7 cats, 20 mg/kg) or 2 consecutive days (15 cats, 10 mg/kg/d) once weekly. All but 1 cat responded with a complete and lasting remission of signs after 1-4 weeks of treatment. Two cats had a short-term skin irritation at the site of the aglépristone injection. Two pregnant cats with FAH aborted after treatment with aglépristone and subsequently developed endometritis. In conclusion, the results of this study demonstrate that FAH in cats can be treated successfully with the progesterone receptor blocker aglépristone.
authors.affiliation: Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, University of Utrecht, The Netherlands.
authors.forename: S
authors.initials: S
authors.lastname: Görlinger
authors.forename: H S
authors.initials: HS
authors.lastname: Kooistra
authors.forename: A
authors.initials: A
authors.lastname: van den Broek
authors.forename: A C
authors.initials: AC
authors.lastname: Okkens
mesh_terms: D000034:Abortion, Veterinary; D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy* / Q000473:pathology; D002415:Cats; D004716:Endometritis / Q000209:etiology / Q000662:veterinary; D004963:Estrenes / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D018226:Fibroadenoma / Q000188:drug therapy* / Q000662:veterinary*; D006965:Hyperplasia / Q000662:veterinary; D007279:Injections, Subcutaneous; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000473:pathology; D010052:Ovariectomy / Q000662:veterinary; D011247:Pregnancy; D011372:Progestins / Q000494:pharmacology; D011980:Receptors, Progesterone; D016896:Treatment Outcome
chemical_list: D004963:Estrenes; D011372:Progestins; D011980:Receptors, Progesterone; C419063:aglepristone